Found 5 matching trials
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer PHASE2 TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 ...
Show More Status
Active Not Recruiting
Location
University of Hawaii
Learn More & Join Trial
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) PHASE1 This is a first-in-human study evaluating the anti-T cell immunoglobulin an...
Show More Status
Active Not Recruiting
Location
GSK Investigational Site
Learn More & Join Trial
Dostarlimab and Cobolimab in Advanced Cervical Cancer PHASE2 This research is being done to determine how effective dostarlimab in combi...
Show More Status
Active Not Recruiting
Location
Beth Israel Deaconess Medical Center
Learn More & Join Trial
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma PHASE2 The purpose of this study is to test the effects of anti-PI-1 inhibitor (TS...
Show More Status
Active Not Recruiting
Location
Georgetown University Medical Center
Learn More & Join Trial
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 PHASE1 Part A: To test the safety and tolerability of combination therapy with Nir...
Show More Location
GSK Investigational Site
Learn More & Join Trial